Profile - To The Moon

Ded

Posts · 17Posts · 17
Following · 0Following · 0
Followers · 0Followers · 0

- DedDed
  ·2021-08-13
  $Catalyst Pharmaceuticals(CPRX)$Go go goooo
  490 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-28
  $High Tide Inc.(HITI)$Go go go
  477 Comment
  1
  Share
  Report
- DedDed
  ·2021-06-28
  $ChargePoint Holdings Inc.(CHPT)$Go go go
  604 Comment
  1
  Share
  Report
- DedDed
  ·2021-06-23
  $Express,(EXPR)$let’s go![Miser]
  361 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-23
  $ChargePoint Holdings Inc.(CHPT)$Go go go![Cool]
  253 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-23
  $Histogenics(OCGN)$?
  374 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-18
  $High Tide Inc.(HITI)$[Spurting]
  245 Comment
  1
  Share
  Report
- DedDed
  ·2021-06-18
  Nice[Strong]
  ChargePoint’s Network Effects Will Make It the Next ‘Shell’
  ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May a
  ChargePoint’s Network Effects Will Make It the Next ‘Shell’
  264 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-17
  Wow
  Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO
  The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the t
  Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO
  211 Comment
  Like
  Share
  Report
- DedDed
  ·2021-06-17
  $ChargePoint Holdings Inc.(CHPT)$[Cool]
  589 1
  3
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3573642293610153","uuid":"3573642293610153","gmtCreate":1610579672328,"gmtModify":1623683742865,"name":"Ded","pinyin":"ded","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.17","exceedPercentage":"80.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":897985423,"gmtCreate":1628868418462,"gmtModify":1676529881769,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","listText":"<a href=\"https://laohu8.com/S/CPRX\">$Catalyst Pharmaceuticals(CPRX)$</a>Go go goooo","text":"$Catalyst Pharmaceuticals(CPRX)$Go go goooo","images":[{"img":"https://static.tigerbbs.com/577232879fad6fb52b8d989dde2a5e0f","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897985423","isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150117323,"gmtCreate":1624889581362,"gmtModify":1703847192981,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>Go go go","text":"$High Tide Inc.(HITI)$Go go go","images":[{"img":"https://static.tigerbbs.com/b60aab03b6e83f72afec21985dfc94b6","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150117323","isVote":1,"tweetType":1,"viewCount":477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":150107201,"gmtCreate":1624888915403,"gmtModify":1703847152020,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150107201","isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121954237,"gmtCreate":1624451373229,"gmtModify":1703837046918,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>let’s go![Miser]&nbsp;","text":"$Express,(EXPR)$let’s go![Miser]","images":[{"img":"https://static.tigerbbs.com/7e33febab7ea9f082d82d94a90198e2b","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121954237","isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121956357,"gmtCreate":1624451221979,"gmtModify":1703837042054,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>Go go go![Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$Go go go![Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121956357","isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121953962,"gmtCreate":1624451043756,"gmtModify":1703837037682,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>?","text":"$Histogenics(OCGN)$?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121953962","isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166454932,"gmtCreate":1624023649726,"gmtModify":1703826842413,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","listText":"<a href=\"https://laohu8.com/S/HITI\">$High Tide Inc.(HITI)$</a>[Spurting]&nbsp;","text":"$High Tide Inc.(HITI)$[Spurting]","images":[{"img":"https://static.tigerbbs.com/9856b4aee333fe53f91b104be5e2001d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166454932","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166453874,"gmtCreate":1624023510798,"gmtModify":1703826834050,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Nice[Strong]&nbsp;","listText":"Nice[Strong]&nbsp;","text":"Nice[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166453874","repostId":"1181667218","repostType":2,"repost":{"id":"1181667218","kind":"news","pubTimestamp":1624008124,"share":"https://ttm.financial/m/news/1181667218?lang=&edition=fundamental","pubTime":"2021-06-18 17:22","market":"us","language":"en","title":"ChargePoint’s Network Effects Will Make It the Next ‘Shell’","url":"https://stock-news.laohu8.com/highlight/detail?id=1181667218","media":"investorplace","summary":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May a","content":"<p><b>ChargePoint</b>&nbsp;(NYSE:<b><u>CHPT</u></b>) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed420b8993199e014fc4d87c875c9dd5\" tg-width=\"300\" tg-height=\"169\"><span>Source: YuniqueB / Shutterstock.com</span></p>\n<p>The catalyst? There are a few of them —</p>\n<ul>\n <li>Recharged growth trade on lower bond yields</li>\n <li>Reinvigorated optimism about EVs and the charging network buildout</li>\n <li>New, rather impressive products from ChargePoint</li>\n</ul>\n<p>This will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.</p>\n<p>Here’s why.</p>\n<p>ChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version of<b>Shell</b>(NYSE:<b><u>RDS-A</u></b>, NYSE:<b><u>RDS-B</u></b>) or<b>Exxon</b>(NYSE:<b><u>XOM</u></b>) by 2030.</p>\n<p>On the surface, this company looks like all other EV charging companies.</p>\n<p>ChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.</p>\n<p>Basically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …</p>\n<p>CHPT Stock: Network Effects Set ChargePoint Apart</p>\n<p>Where ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.</p>\n<p>It’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.</p>\n<p>Its size is especially significant because of network effects.</p>\n<p>Of ChargePoint’s commercial clients, more than 60% of&nbsp;<b>Fortune 500</b>&nbsp;companies employ ChargePoint charging stations at their corporate offices. If companies such as<b>Facebook</b>(NASDAQ:<b><u>FB</u></b>),<b>Netflix</b>(NASDAQ:<b><u>NFLX</u></b>),<b>Salesforce</b>(NYSE:<b><u>CRM</u></b>),<b>Microsoft</b>(NASDAQ:<b><u>MSFT</u></b>) and<b>Adobe</b>(NASDAQ:<b><u>ADBE</u></b>) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.</p>\n<p>ChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.</p>\n<p>From a consumer-facing perspective, ChargePoint is also setting itself up for future success.</p>\n<p>The company hasteamed up with auto makerslike Mercedes-owner&nbsp;<b>Daimler AG</b>(OTCMKTS:<b><u>DMLRY</u></b>) and<b>BMW</b>(OTC:<b><u>BMWYY</u></b>) tointegrate the locations of its charging stationsinto in-car navigation systems.</p>\n<p>ChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.</p>\n<p>Again, it all comes down to ChargePoint’s unmatched network effects.</p>\n<p>Which is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.</p>\n<p>Naturally, that would mean huge upside potential for CHPT stock.</p>\n<p>Which is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChargePoint’s Network Effects Will Make It the Next ‘Shell’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChargePoint’s Network Effects Will Make It the Next ‘Shell’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHPT":"ChargePoint Holdings Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2021/06/chargepoints-network-effects-will-make-them-the-next-shell/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181667218","content_text":"ChargePoint (NYSE:CHPT) stock took a bit hit in March and April but has bounced back nicely in May and June. It’s now pushing its way towards all-time highs.\nSource: YuniqueB / Shutterstock.com\nThe catalyst? There are a few of them —\n\nRecharged growth trade on lower bond yields\nReinvigorated optimism about EVs and the charging network buildout\nNew, rather impressive products from ChargePoint\n\nThis will all last. EVs will take over the world, charging stations will replace gas pumps and ChargePoint will be the biggest charging company in the world when all is said and done.\nHere’s why.\nChargePoint is North America’s largest operator of electric vehicle charging stations. It should be able to leverage their early entry into the market as well as its size. Thanks to network effects, it could turn into the EV version ofShell(NYSE:RDS-A, NYSE:RDS-B) orExxon(NYSE:XOM) by 2030.\nOn the surface, this company looks like all other EV charging companies.\nChargePoint operate on the standard hardware-plus-software model — selling both physical EV charging ports and end-to-end software platforms to manage them. Its assortment of chargers includes L2 chargers and a smattering of DC fast chargers. And it costs money, around $2 to $5, to use these chargers.\nBasically, ChargePoint is doing what everyone else is doing, but there’s so much more to it than that …\nCHPT Stock: Network Effects Set ChargePoint Apart\nWhere ChargePoint shines is in its unparalleled size and dominance in the EV charging station market.\nIt’s seven times larger than its nearest competitor, with over 100,000 charging ports and 73% of L2 EV charging stations.\nIts size is especially significant because of network effects.\nOf ChargePoint’s commercial clients, more than 60% of Fortune 500 companies employ ChargePoint charging stations at their corporate offices. If companies such asFacebook(NASDAQ:FB),Netflix(NASDAQ:NFLX),Salesforce(NYSE:CRM),Microsoft(NASDAQ:MSFT) andAdobe(NASDAQ:ADBE) already utilize ChargePoint chargers — which shows other companies who to turn to when they want to install their own EV charging stations — ChargePoint should be able to leverage this array of existing customers to win more and more big-name contracts.\nChargePoint is on its way to dominating the commercial workplace vertical of the EV market for the near- to long-term future.\nFrom a consumer-facing perspective, ChargePoint is also setting itself up for future success.\nThe company hasteamed up with auto makerslike Mercedes-owner Daimler AG(OTCMKTS:DMLRY) andBMW(OTC:BMWYY) tointegrate the locations of its charging stationsinto in-car navigation systems.\nChargePoint also offers a popular app that enables drivers to locate its charging stations, see if they’re currently in-use or not and check prices. The app keeps ChargePoint on consumers’ minds, which will help the company dominate the at-home, residential EV-charging market.\nAgain, it all comes down to ChargePoint’s unmatched network effects.\nWhich is why I believe that, as EVs gradually replace gas cars, ChargePoint has the potential to replace Shell as the leading operator of “refueling” stations.\nNaturally, that would mean huge upside potential for CHPT stock.\nWhich is why CHPT is one of my top picks in EV charging. And long-term, you can bet that CHPT stock will score investors massive returns.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163370080,"gmtCreate":1623860662640,"gmtModify":1703821852932,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163370080","repostId":"2143792542","repostType":4,"repost":{"id":"2143792542","kind":"news","pubTimestamp":1623854323,"share":"https://ttm.financial/m/news/2143792542?lang=&edition=fundamental","pubTime":"2021-06-16 22:38","market":"us","language":"en","title":"Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2143792542","media":"Yahoo Finance","summary":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the t","content":"<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows <a href=\"https://laohu8.com/S/AONE\">one</a> of the disease's most debilitating symptoms: cognitive decline.</p>\n<p>In a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.</p>\n<p>Ricks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.</p>\n<p>\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in <a href=\"https://laohu8.com/S/AONE.U\">one</a> trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.</p>\n<p>Biogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.</p>\n<p>\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"</p>\n<p>\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"</p>\n<p>\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"</p>\n<p>The approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.</p>\n<p>\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.</p>\n<p>\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.</p>\n<h2>'There are huge unmet needs'</h2>\n<p>Biogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.</p>\n<p>\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"</p>\n<p>The backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"</p>\n<p>Speaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.</p>\n<p>\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"</p>\n<p>\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/biogen-alzheimers-drug-approval-was-surprising-for-a-lot-of-people-eli-lilly-ceo-142643673.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143792542","content_text":"The approval this month of an Alzheimer's drug from biotech company Biogen (BIIB) — along with the treatment's eye-popping $56,000 per year price tag — set off a wave of criticism over scant evidence that the drug slows one of the disease's most debilitating symptoms: cognitive decline.\nIn a new interview, David Ricks — CEO of rival pharmaceutical company Eli Lilly (LLY) — added his voice to those skeptical of the drug.\nRicks called the approval \"surprising,\" describing the treatment's trial data as \"pretty controversial.\" The decision from the Food and Drug Administration (FDA) demonstrates a shift in \"the bar\" for Alzheimer's drug approvals that will spur investment in drugs from other companies seeking the same green light, Ricks told Yahoo Finance.\n\"We're still kind of processing what occurred,\" says Ricks, whose company is also developing an Alzheimer's drug and saw a stock bump after the approval. \"I think it was surprising for a lot of people.\"\nTwo trials of Biogen's drug, Aduhelm, showed that it reduces amyloid-protein plaques in the brain that are associated with Alzheimer's and the cognitive decline it induces. But in one trial the drug showed no alleviation of cognitive decline, and in the other it showed a minor effect on such decline that barely exceeded that produced by a placebo, the New Yorker reported.\nBiogen initially scrapped the trials but later revisited them and found encouraging results, in part due to the inclusion of patients who finished the trial in the period after it had been abandoned.\n\"The data set itself was pretty controversial,\" Ricks says. \"This happens in medical research, where the gold standard for approval is you call your shot, and then you hit your shot, like Babe Ruth pointing at the left field and then hitting his home run there.\"\n\"Here, something different happened, and this happens pretty frequently in medical development,\" he adds. \"Where they call their shot, and then they ended up stopping a study and then looking back and seeing something more encouraging.\"\n\"That's not a normal process,\" he says. \"And having worked ourselves in Alzheimers for the last 34 years, and we've had lots of failures, too. And on look back, sometimes you become encouraged. But really, it's important that I think drug companies generate very solid evidence for the use of our products.\"\nThe approval marks a newfound willingness from the FDA to give the go-ahead for Alzheimer's drugs that address biological signs of the disease even if they don't show efficacy treating the underlying disease itself, Ricks said.\n\"The FDA actually in the end did not say that those results were solid evidence, what they said was that the drug moves what's known as a biomarker or a precursor to the disease in a very meaningful way, which I think is without dispute,\" Ricks says.\n\"But then [the FDA] said that that biomarker or precursor is enough for approval, so in a way sort of shifting the bar or the policy for Alzheimer's approvals,\" he adds.\n'There are huge unmet needs'\nBiogen's drug is delivered through multiple intravenous injections, likely requiring visits with a physician. For his part, Biogen CEO Michel Vounatsos celebrated the approval and expressed confidence that the drug will help Alzheimer's patients.\n\"We believe this first-in-class medicine will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come,\" he told USA Today. \"We are grateful for the contributions of thousands of patients and caregivers who participated in our clinical trials, as well as for the dedication of our scientists and researchers.\"\nThe backlash against the approval escalated last week with the resignation of three scientists who served on a committee that advised the Food and Drug Administration (FDA) on the treatment. One of the scientists, Harvard Medical School professor Aaron Kesselheim, told The New York Times it \"might be the worst approval decision that the F.D.A. has made that I can remember.\"\nSpeaking to Yahoo Finance, Ricks said the approval does offer some hope for over 6 million people living with Alzheimer's, and will incentivize other companies to pursue therapies for the disease.\n\"We know there are huge unmet needs,\" Ricks says. \"So in some sense, that's a hope for patients.\"\n\"I think it will also unleash a lot of investment from companies to prove the same thing with other drugs because it is an easier task,\" he adds.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163344565,"gmtCreate":1623860630857,"gmtModify":1703821850965,"author":{"id":"3573642293610153","authorId":"3573642293610153","name":"Ded","avatar":"https://static.tigerbbs.com/d1f5be513a29608a816e336ccd99a614","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573642293610153","authorIdStr":"3573642293610153"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHPT\">$ChargePoint Holdings Inc.(CHPT)$</a>[Cool]&nbsp;","text":"$ChargePoint Holdings Inc.(CHPT)$[Cool]","images":[{"img":"https://static.tigerbbs.com/9b459b32a44edb67cce1e75099dad8b3","width":"828","height":"1590"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/163344565","isVote":1,"tweetType":1,"viewCount":589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}